Langopept Phase II placebo-controlled COPD trial registration
Planned study · 2023
- Registered population or design
- 200 planned participants with moderate-to-severe chronic obstructive pulmonary disease (COPD). Actual enrollment and arm sizes are unavailable.
- Results availability
- PeptidPRO’s double-blind COPD trial lists 200 planned participants. Clinomir marks the study completed. Actual enrollment, doses administered and results remain unavailable.
Reported findings and study design
The patent gives no measured outcomes
Multicenter, double-blind, randomized, parallel-group placebo-controlled design. ClinLine lists investigators T. I. Ishina, V. V. Popov and N. D. Krasnopeeva.
Dose, route and schedule
The registry lists a 5 mg lyophilized formulation for intramuscular injection and a placebo control. It does not give the per-visit dose, frequency or treatment duration.
Protocol source ↗ · ClinLine trial entry and Clinomir sponsor listing for PeptidPRO.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Planned enrollment | 200 participants |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- The registry target was 200. Clinomir gives an administrative completion status without participant flow, study endpoint data, or adverse-event tables.
Source details
Trial registry reproduction
ClinLine trial entry and Clinomir sponsor listing for PeptidPRO.
Sources checked
Citation
PeptidPRO. Langopept Phase II placebo-controlled COPD trial registration Russian clinical-trial registry record, authorization 262, 5 May 2023. Protocol LNG-11-2022.